MAM
PTGX icon

Meeder Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Meeder Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-399
Closed -$3K – 2379
2020
Q1 		$3K Sell
399
-811
-67% -$6.08K ﹤0.01% 1980
2019
Q4 		$9K Sell
1,210
-2,240
-65% -$22.2K ﹤0.01% 1594
2019
Q3 		$41K Buy
3,450
+3,225
+1,433% +$40.6K ﹤0.01% 1075
2019
Q2 		$3K Sell
225
-419
-65% -$4.63K ﹤0.01% 1803
2019
Q1 		$8K Sell
644
-273
-30% -$2.41K ﹤0.01% 1300
2018
Q4 		$6K Buy
917
+112
+14% +$888 ﹤0.01% 1376
2018
Q3 		$8K Buy
805
+540
+204% +$4.65K ﹤0.01% 1215
2018
Q2 		$1.78K Sell
265
-78
-23% -$599 ﹤0.01% 1431
2018
Q1 		$2K Sell
343
-58
-14% -$1.09K ﹤0.01% 1389
2017
Q4 		$8K Buy
+401
New +$7.11K ﹤0.01% 1197
2017
Q3 		– Sell
-79
Closed -$1K – 1733
2017
Q2 		$1K Buy
79
+25
+46% +$267 ﹤0.01% 1542
2017
Q1 		$1K Buy
+54
New +$870 ﹤0.01% 1543

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Meeder Asset Management's PTGX Position: Q2 2020 in Review

Meeder Asset Management sold out of Protagonist Therapeutics (PTGX) in Q2 2020, closing a stake of 399 shares — an estimated $3K sold.

Meeder Asset Management first reported a position in PTGX in Q1 2017 and held it in 12 quarters. The position peaked at $41K in Q3 2019. 85 funds tracked by Wall St. Rank hold PTGX as of Q2 2020.

  • Meeder Asset Management reported no remaining Protagonist Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 399 Protagonist Therapeutics shares in Q2 2020, an estimated $3K.
  • Meeder Asset Management first reported a position in Protagonist Therapeutics in Q1 2017 and held it in 12 quarters.
  • Meeder Asset Management's Protagonist Therapeutics position peaked at $41K in Q3 2019.
  • 85 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.